NSAID Eye Drops: Nepafenac, Bromfenac and the Prevention of Cystoid Macular Oedema
This article is for educational purposes for healthcare professionals. It does not constitute medical advice and does not replace the Instructions for Use supplied with each product. Clinical decisions should be based on professional judgement, the individual patient's condition, and current regulatory guidance.
Topical non-steroidal anti-inflammatory drugs have quietly become standard of care in cataract surgery — not for their original approved purpose of maintaining intraoperative mydriasis, but for what OCT taught us: clinically silent macular thickening after phacoemulsification is common, and preventing it improves the quality of vision patients actually notice. Pseudophakic cystoid macular oedema (CME) remains the commonest cause of unexpected visual shortfall after uncomplicated surgery. NSAIDs, which block cyclo-oxygenase-driven prostaglandin synthesis and thereby the breakdown of the blood-retinal barrier, are the prophylactic tool of choice alongside corticosteroids. This article compares nepafenac and bromfenac — the two dominant molecules in Indian practice — and sets out a rational protocol.
Mechanism: Why NSAIDs Matter After Surgery
Surgical trauma activates phospholipase A2 in the iris and ciliary body, releasing arachidonic acid. Corticosteroids act upstream, blocking the whole cascade; NSAIDs act at the cyclo-oxygenase (COX-1/COX-2) branch, preventing conversion to prostaglandins — the mediators most directly responsible for vasodilation, blood-aqueous and blood-retinal barrier breakdown, and the miosis that complicates surgery. The two classes are complementary, not redundant, which is why combined steroid-plus-NSAID regimens outperform either alone for CME prevention in higher-risk eyes.
Nepafenac: The Prodrug With a Penetration Advantage
Nepafenac 0.1% is pharmacologically unusual: it is a prodrug with low intrinsic COX activity that penetrates the cornea rapidly and is deaminated by intraocular hydrolases to amfenac, the potent active species. The design intent — supported by the pharmacokinetic literature — is superior transcorneal transit with sustained intraocular generation of active drug:
- Walters et al. (J Cataract Refract Surg, 2007): in vivo human aqueous sampling showed nepafenac achieved greater ocular bioavailability than ketorolac or bromfenac comparators, with the prodrug-reservoir behaviour the design predicted.
- Lane et al. (JCRS, 2007): the pivotal randomised trial of nepafenac 0.1% for prevention and treatment of pain and inflammation after cataract surgery — significantly more patients pain-free and with controlled anterior chamber inflammation versus vehicle.
- Wolf et al. (JCRS, 2007): retrospective but influential — visually significant CME occurred in 0 of 210 eyes treated with nepafenac plus steroid versus 5 of 240 with steroid alone after uneventful phacoemulsification.
Dosing is classically TID from one day preoperatively through 2–4 weeks postoperatively; a once-daily 0.3% presentation exists internationally. Nepalux (nepafenac 0.1%) brings the prodrug profile — fast onset, strong corneal and scleral penetration, and a safety record across anterior and posterior segment postoperative use — to Indian protocols.
Bromfenac: Potent, Once or Twice Daily
Bromfenac 0.09% is a direct-acting, highly potent COX inhibitor (bromination enhances lipophilicity and corneal penetration), approved for postoperative inflammation and pain:
- Donnenfeld et al. (Ophthalmology, 2007): the pivotal trials demonstrating efficacy for post-cataract inflammation and pain versus vehicle.
- Cable's large retrospective series (presented at ASCRS) of over 1,000 eyes dosed from 3 days preoperatively found CME in only 0.5% — among the lowest reported rates.
- Once-daily and twice-daily regimens are its practical selling point in adherence-limited populations.
Head-to-head nepafenac-versus-bromfenac comparisons are small and inconsistent; pilot OCT studies show broadly equivalent macular outcomes. The honest summary: molecule choice matters less than actually using one in at-risk eyes, starting preoperatively, and continuing long enough (the inflammatory CME window peaks at 4–6 weeks).
Evidence for CME Prevention: What Guidelines Reflect
The ESCRS PREMED study (Wielders et al., JCRS 2018) — a randomised multicentre trial — found that in non-diabetic routine cataract patients, adding a topical NSAID to steroids reduced the risk of clinically meaningful CME, though absolute benefit was modest in low-risk eyes; in diabetics, the protective effect of combination therapy was larger and clearer. Cochrane reviews of topical NSAIDs after cataract surgery support reduced odds of CME while noting outcome-measure heterogeneity. The synthesis most surgeons now apply:
- Routine low-risk eyes: NSAID optional; steroid alone is defensible.
- Any risk factor — diabetes (with or without retinopathy), epiretinal membrane, uveitis history, vein occlusion, prior CME in either eye, posterior capsule rupture, prostaglandin-analogue use: NSAID plus steroid is the standard, started 1–3 days preoperatively and continued 4–6 weeks.
Recognising and Managing Established CME
Prophylaxis fails sometimes, and the postoperative surgeon should treat CME as an expected event with a defined pathway rather than a surprise. Suspect it when vision plateaus or declines after an initially good result, typically at 3–6 weeks, with a quiet anterior segment — the classic "worse than the slit lamp looks" presentation. Confirm with macular OCT (intraretinal cystoid spaces, increased central thickness); fluorescein angiography's petaloid leakage is now largely of historical interest. First-line treatment is the combination of a potent topical NSAID (TID nepafenac or BD bromfenac) with a potent steroid for 6–8 weeks; most acute pseudophakic CME resolves on this. Persistent or severe cases escalate to periocular or intravitreal steroid and, in refractory disease, anti-VEGF or vitreoretinal intervention. The two prognostic lessons: early OCT beats late guesswork, and most acute CME treated promptly leaves no permanent deficit — which is precisely why preventing it is worth a bottle.
Safety: The Corneal Warning That Must Be Said
Topical NSAIDs carry a rare but serious corneal toxicity — keratolysis (corneal melt) — reported most with generic diclofenac formulations historically, and associated with compromised surfaces: severe dry eye, rheumatoid arthritis, diabetes with neurotrophic changes, repeated surgery, and concurrent epithelial defects. Practical safeguards:
- Never prescribe over an open epithelial defect beyond the immediate refractive-surgery analgesia window.
- Stop at the first sign of corneal thinning, persistent epitheliopathy or stromal infiltrate.
- Use the shortest effective course on compromised surfaces; prefer steroid-only strategies where the surface is fragile.
- Expect transient stinging; investigate persistent pain, which is not a normal NSAID effect.
One formulation detail matters in practice: nepafenac 0.1% is a suspension. Patients must shake the bottle — an unshaken suspension delivers a fraction of labelled dose in the first drops and an overdose in the last, a quiet source of variable response between patients on identical prescriptions.
Other Ophthalmic Uses of Topical NSAIDs
Beyond cataract surgery, the class earns its place in several recurring scenarios:
- Post-refractive surgery analgesia: PRK pain is substantial in the first 48–72 hours; a short NSAID course (with a bandage contact lens) is standard comfort management, after which the drop must stop — the corneal toxicity warnings apply with full force to the ablated surface.
- Allergic conjunctivitis adjunct: ketorolac has an anti-itch indication historically; dual-acting antihistamines have largely superseded this role.
- Episcleritis and mild scleritis: topical NSAIDs are a reasonable first step for episcleritis, though efficacy is modest and oral NSAIDs remain the backbone for true scleritis.
- CME beyond cataract: post-vitrectomy, uveitic and diabetic macular oedema adjunct roles exist with variable evidence; these are specialist decisions, typically NSAID-plus-steroid combinations over 6–12 weeks.
- Maintenance of mydriasis: the original indication — preoperative dosing reduces intraoperative miosis, still relevant in non-routine cases without intracameral mydriatics.
NSAIDs and Steroids: Getting the Combination Right
Surgeons sometimes frame NSAID-versus-steroid as a choice; the pharmacology says it is a partnership. Steroids block phospholipase A2 upstream, suppressing the entire arachidonic acid cascade including the lipoxygenase branch; NSAIDs block only the cyclo-oxygenase branch but do so with particular effect on the prostaglandin-mediated vascular permeability that drives CME. In low-risk eyes the steroid's breadth suffices. In at-risk eyes, the steroid's upstream blockade plus the NSAID's targeted barrier protection is additive — the PREMED and older combination data point the same way. Practically: run the two in parallel from day one rather than adding the NSAID when inflammation declares itself; prophylaxis that waits for the disease it prevents is treatment, and established CME is slower and harder to reverse than prevented CME.
Cost, Availability and the Indian Formulary Decision
Both molecules are available as quality Indian generics at a fraction of originator pricing, which removes most of the historical cost argument against routine prophylaxis in at-risk eyes. When selecting a brand for a surgical protocol, the variables that matter are concentration accuracy (a 0.1% suspension must deliver 0.1%), suspension quality (uniform resuspension, no flocculation), preservative choice for the perioperative window, and batch-to-batch consistency — the WHO-GMP audit questions that distinguish a reliable manufacturer from a cheap one. For high-volume surgeons, standardising one NSAID across the unit simplifies nursing education, pharmacy stocking and the written protocol that determines whether the regimen survives contact with real patients.
A Practical Postoperative NSAID Protocol
| Risk stratum | NSAID regimen | Companion therapy |
|---|---|---|
| Routine, no risk factors | Optional; if used: nepafenac TID or bromfenac OD–BD, day −1 to week 2–4 | Standard steroid taper; antibiotic prophylaxis (e.g., Moxilux) |
| Diabetic / ERM / prior CME / PCR | NSAID day −3 to week 4–6, do not stop early | Steroid plus NSAID in parallel; OCT at 4–6 weeks if symptomatic |
| Established CME | NSAID TID + potent steroid, often with periocular steroid | Escalate per retina protocol if unresolved by 6–8 weeks |
Sequence drops five minutes apart, suspensions shaken. And remember that CME prophylaxis is a conversation about expectations: patients paying for premium refractive outcomes are precisely those in whom subclinical macular thickening produces disproportionate dissatisfaction — a strong argument for liberal NSAID prophylaxis in that group.
Frequently Asked Questions
What is nepafenac and how does it differ from other NSAID drops?
Nepafenac is a prodrug that crosses the cornea rapidly and is converted inside the eye to amfenac, the active COX inhibitor. This gives high intraocular bioavailability with sustained active-drug generation — the penetration advantage demonstrated in human aqueous sampling studies (Walters et al., JCRS 2007).
Should every cataract patient get an NSAID drop?
Not necessarily. For routine non-diabetic eyes, steroid alone is defensible; ESCRS PREMED showed the absolute NSAID benefit is modest in low-risk patients. For any eye with diabetes, epiretinal membrane, uveitis, vein occlusion, prior CME or capsule rupture, combined NSAID-plus-steroid prophylaxis is the standard.
When should NSAID drops be started around cataract surgery?
Ideally 1–3 days preoperatively to build tissue levels before surgical trauma, continued through the inflammatory window — at least 2 weeks in routine use and 4–6 weeks in at-risk eyes, since pseudophakic CME peaks at 4–6 weeks.
What is the most serious risk of topical NSAIDs?
Corneal melt (keratolysis) — rare, but sight-threatening, and associated with compromised ocular surfaces (severe dry eye, rheumatoid disease, neurotrophic corneas, epithelial defects). Stop immediately for corneal thinning or persistent epitheliopathy, and avoid prolonged courses on fragile surfaces.
Nepafenac or bromfenac — which should I choose?
Comparative evidence shows broadly equivalent anti-inflammatory and CME-prevention efficacy. Choose on dosing convenience (bromfenac OD–BD versus nepafenac TID), tolerability, cost and formulary availability; adherence to the full course matters more than the molecule.
This article is for educational purposes for healthcare professionals and does not replace clinical judgement. CME prophylaxis should be individualised to ocular and systemic risk factors.
Oculentis Medical's Nepalux (nepafenac 0.1%) brings prodrug penetration to postoperative care. To evaluate it in your surgical protocol, request a sample or contact our team.